Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease

[1]  S. Vogt,et al.  COPPER AND ANGIOGENESIS: UNRAVELLING A RELATIONSHIP KEY TO CANCER PROGRESSION , 2009, Clinical and experimental pharmacology & physiology.

[2]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Czene,et al.  The Heritability of Prostate Cancer in the Nordic Twin Study of Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[4]  David Levine,et al.  GWASTools: an R/Bioconductor package for quality control and analysis of genome-wide association studies , 2012, Bioinform..

[5]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[6]  A Jakubowska,et al.  An inherited NBN mutation is associated with poor prognosis prostate cancer , 2012, British Journal of Cancer.

[7]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[8]  Andrew Carroll,et al.  WGSA: an annotation pipeline for human genome sequencing studies , 2015, Journal of Medical Genetics.

[9]  D. Conti,et al.  Using extreme phenotype sampling to identify the rare causal variants of quantitative traits in association studies , 2011, Genetic epidemiology.

[10]  David Levine,et al.  A high-performance computing toolset for relatedness and principal component analysis of SNP data , 2012, Bioinform..

[11]  R. Wilson,et al.  Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[12]  K. Cooney,et al.  Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy , 2014, BJU international.

[13]  M. Rieder,et al.  Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. , 2012, American journal of human genetics.

[14]  Shaun M. Purcell,et al.  Statistical power and significance testing in large-scale genetic studies , 2014, Nature Reviews Genetics.

[15]  D. Easton,et al.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients , 2011, British Journal of Cancer.

[16]  K. Pietras,et al.  ALK1 as an emerging target for antiangiogenic therapy of cancer. , 2011, Blood.

[17]  Lester F. Lau,et al.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets , 2011, Nature Reviews Drug Discovery.

[18]  F. Maquart,et al.  Lumican inhibits angiogenesis by interfering with α2β1 receptor activity and downregulating MMP-14 expression. , 2011, Thrombosis research.

[19]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[20]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[21]  Peter Kraft,et al.  A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer , 2014, Nature Genetics.

[22]  L. Byers,et al.  Giving AXL the axe: targeting AXL in human malignancy , 2017, British Journal of Cancer.

[23]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[24]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[25]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[26]  Krishna R. Kalari,et al.  Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer , 2016, BMJ Open.

[27]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[28]  F. Montorsi,et al.  New surgical approaches for clinically high-risk or metastatic prostate cancer , 2017, Expert review of anticancer therapy.

[29]  A. Maity,et al.  Molecular Neuroscience Review Article , 2011 .

[30]  Tomas Lindahl,et al.  Human DNA repair genes, 2005. , 2005, Mutation research.

[31]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[32]  A. Jakubowska,et al.  NBS1 Is a Prostate Cancer Susceptibility Gene , 2004, Cancer Research.

[33]  R. Eeles,et al.  Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease , 2014, British Journal of Cancer.

[34]  R. Beroukhim,et al.  Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins , 2014, Nature Genetics.

[35]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[36]  Trevor J Pugh,et al.  Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.

[37]  Richard D. Wood,et al.  Human DNA Repair Genes , 2001, Science.

[38]  K. Cooney,et al.  Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. , 2017, European urology.

[39]  J. Carpten,et al.  Germline mutations in HOXB13 and prostate-cancer risk. , 2012, The New England journal of medicine.

[40]  Jian Wu,et al.  Sirtuin 3 Deficiency Accelerates Hypertensive Cardiac Remodeling by Impairing Angiogenesis , 2017, Journal of the American Heart Association.

[41]  A. Thorner,et al.  Mitochondrial HEP27 Is a c-Myb Target Gene That Inhibits Mdm2 and Stabilizes p53 , 2010, Molecular and Cellular Biology.

[42]  R. Eeles,et al.  Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  Xiaowei Zhan,et al.  RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data , 2016, Bioinform..

[44]  S. Seal,et al.  The ICR1000 UK exome series: a resource of gene variation in an outbred population , 2015, F1000Research.

[45]  P. Scardino,et al.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study , 2013, BMJ : British Medical Journal.

[46]  D. Easton,et al.  Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. , 1997, British journal of urology.

[47]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[48]  Li Li,et al.  Incorporating Prior Biologic Information for High-Dimensional Rare Variant Association Studies , 2013, Human Heredity.

[49]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[50]  Chris Mungall,et al.  AmiGO: online access to ontology and annotation data , 2008, Bioinform..

[51]  W. Jiang,et al.  Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (Review) , 2015, International journal of molecular medicine.

[52]  G. Abecasis,et al.  Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data. , 2012, American journal of human genetics.

[53]  Kai Wang,et al.  wANNOVAR: annotating genetic variants for personal genomes via the web , 2012, Journal of Medical Genetics.

[54]  M. Mongiat,et al.  Extracellular Matrix, a Hard Player in Angiogenesis , 2016, International journal of molecular sciences.

[55]  W. Kao,et al.  Lumican Exhibits Anti-Angiogenic Activity in a Context Specific Manner , 2013, Cancer Microenvironment.

[56]  R. Eeles,et al.  Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. , 2015, European urology.

[57]  Ali Amin Al Olama,et al.  Prostate cancer meta-analysis from more than 143,000 men identifies 57 novel prostate cancer susceptibility loci , 2016 .

[58]  K. Pietras,et al.  Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function. , 2016, Biochemical Society transactions.

[59]  Younghun Jung,et al.  Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow , 2016, Scientific Reports.

[60]  C. Fan,et al.  Tumorigenesis and Neoplastic Progression Molecular Characterization of Human Breast Tumor Vascular Cells , 2008 .

[61]  T. Walsh,et al.  Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.

[62]  David V Conti,et al.  Incorporating model uncertainty in detecting rare variants: the Bayesian risk index , 2011, Genetic epidemiology.